Last reviewed · How we verify
NCT03654794: DIFF-TAC
Study of the Cellular Diffusion of Tacrolimus Across the Membrane of Mononuclear Cells
trial testing Cell pharmacokinetics of tacrolimus in Hemochromatosis in 26 participants. Completed in 6 July 2017.
6 July 2017
Quick facts
| Lead sponsor | Rennes University Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 26 |
| Start date | 24 October 2013 |
| Primary completion | 6 July 2017 |
| Estimated completion | 6 July 2017 |
| Sites | 1 location across France |
Drugs / interventions tested
- Cell pharmacokinetics of tacrolimus — full drug profile →
Conditions studied
- Hemochromatosis — all drugs for Hemochromatosis →
Sponsor
Rennes University Hospital
Who can join
18 and older, any sex, with Hemochromatosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pharmacokinetics of tacrolimus are highly variable and may result in graft rejection (underdosing) or toxicity (overdosing). The risk of transplant rejection and the toxicity of tacrolimus can be reduced by pharmacological therapeutic monitoring of the molecule, based on the measurement of residual blood concentrations. Nevertheless, some patients are victims of rejections or toxic signs even though their blood concentrations are in the therapeutic target. The aim of the study is to describe the pharmacokinetics of tacrolimus diffusion in mononuclear cells as well as the kinetics of effect of the drug on its target protein
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03654794
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hemochromatosis
Currently open trials in the same condition.
- NCT00007150 — Treatment of Hemochromatosis · Phase 2 · active not recruiting
Other Rennes University Hospital trials
Trials by the same sponsor.
- NCT07527949 — PASTRAMI : Patient-specific Statistics for Microstructure-augmented Connectomics · NA · not yet recruiting
- NCT07449832 — Sperm Epigenome in Hodgkin Lymphoma · NA · not yet recruiting
- NCT06950398 — Normothermic Oxygenated Perfusion (NMP) Viability Testing Before Transplantation of Discarded Livers · Phase 2 · not yet recruiting
- NCT07188753 — Randomized Controlled Trial Testing the Efficacy of Transcranial Magnetic Stimulation by Accelerated & High-dose Theta-b · NA · not yet recruiting
- NCT06898099 — Evaluation of the Efficacy of E2R Hypnotherapy in the Management of Chronic Insomnia in Primary Care (HypERR) · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03654794 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rennes University Hospital
- Last refreshed: 4 September 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03654794.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing